Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ChromaDex, Inc.
In response to what it says was unexpected airing of ChromaDex' ongoing disputes with Elysium Health, CRN will require speakers at its events to submit materials its review. Chromadex says CRN asked for the type of presentation its chairman made while Elysium Health wasn’t surprised a ChromaDex executive would comment on the litigation.
Marking Coty’s fourth CEO appointment in less than four years, current chairman Peter Harf will lead the firm’s newly created executive committee, which also includes Coty’s CFO and Gordon von Bretten, announced on 28 May as Coty’s first-ever chief transformation officer. Von Bretten joins Coty from investment firm KKR, which is buying Coty’s professional beauty and retail hair-care businesses.
In its third-quarter earnings call, Coty leadership discussed promising “green shoots” and the firm’s highly focused strategic priorities in the shadow of the COVID-19 pandemic.
FDA extends deadline through 23 May for comments on draft guidance for homeopathic industry oversight; Clif Bar changes character on packaging for the first time in 28 years to honor female athletes; ABC announces Duke, Kronenberg and Champion awards; and probiotics firm ZBiotics raised funding for additional development.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Healthspan Research, LLC, ChromaPharma Inc, ChromaDex Corp.